Yes. After promising fibrosis reversal in Mash, CYDY announced other companies/institutions were interested in researching LL fibrosis reversal in organs other than the liver. I believe cardio-pulmonary was mentioned in the letter to shareholders? But yes, cardio and vascular fibrosis reduction is on the radar.